Evidence map›Paper›PMID 28626370›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2017

Donor Safety in Haemapheresis: Development of an Internet-Based Registry for Comprehensive Assessment of Adverse Events from Healthy Donors.

Hans-Gert Heuft, Eike Fischer, Tina Weingand, Thomas Burkhardt, Gerda Leitner, Hagen Baume, Jörg-Peter Schmidt, Andreas Buser, Gabriele Fauchald, Ute Reinicke Voigt and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Hans-Gert HeuftInstitute for Transfusion Medicine, Hanover Medical School, Hanover, Germany.
Eike FischerAix-Scientifics®, Clinical Research Organisation, Aachen, Germany.
Tina WeingandBlood Donation Service, Swiss Red Cross, Luzern, Switzerland.
Thomas BurkhardtGerman Red Cross Blood Donation Service North-East, Plauen, Germany.
Gerda LeitnerUniversity Clinic for Blood Group Serology and Transfusion Medicine, Vienna, Austria.
Hagen BaumeGerman Red Cross Donation Service NSTOB, Institute Oldenburg, Oldenburg, Germany.
Jörg-Peter SchmidtGerman Red Cross Blood Donation Service NSTOB, Institute Dessau, Dessau, Germany.
Andreas BuserUniversity Blood Donation Service Basel, Basel, Switzerland.
Gabriele FauchaldBavarian Red Cross, Munich, Germany.
Ute Reinicke VoigtInstitute for Transfusion Medicine, University Clinic Münster, Münster, Germany.
Behrouz Mansouri-TaleghaniMedical Directorate of the Swiss Red Cross, Bern, Switzerland.
German Red Cross · DESwiss Red Cross · CHAixtron (Germany) · DEMedizinische Hochschule Hannover · DEUniversity Clinic of Traumatology · ATUniversity Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, there is an extensive but highly inconsistent body of literature regarding donor adverse events (AEs) in haemapheresis. As the reports diverge with respect to types and grading of AEs, apheresis procedures and machines, the range of haemapheresis-related AEs varies widely from about 0.03% to 6.6%.

methodsThe German Society for Transfusion Medicine and Immunohaematology (DGTI) formed a 'Haemapheresis Vigilance Working Party' (Arbeitsgemeinschaft Hämapheresevigilanz; AGHV) to create an on-line registry for comprehensive and comparable AE assessment with all available apheresis devices in all types of preparative haemapheresis: plasmapheresis (PLS), plateletpheresis (PLT), red blood cell apheresis, all kind of leukaphereses (autologous/allogeneic blood stem cell apheresis, granulocyte apheresis, lymphocyte/monocyte apheresis) and all possible types of multi-component apheresis. To ensure the comparability of the data, the AGHV adopted the 'Standard for Surveillance of Complications Related to Blood Donation' from the International Society for Blood Transfusion in cooperation with the International Haemovigilance Network (IHN) and the American Association of Blood Banks for AE acquisition and automated evaluation. The registry is embedded in a prospective observational multi-centre study with a study period of 7 years.

resultsA preliminary evaluation encompassed the time period from January, 2012 to December, 2015. During this time, the system proved to be safe and stable. Out of approximately 345,000 haemaphereses 16,477 AEs were reported (4.9%) from 20 participating centres. The majority of AEs occurred in PLSs (63%), followed by PLT (34.5%) and SC (2.2%). Blood access injuries (BAI) accounted for about 55% of the supplied AEs, whereas citrate toxicity symptoms, vasovagal reactions and technical events (e.g. disposable leakages, software failures) rather equally affected haemaphereses at 8-15%. Out of 12,348 finalized AEs, 8,759 (70.1%) were associated with a procedure-related break-off, with BAI being the prevailing cause (5,463/8,759; 62.4%). An automated centre- and procedure-specific AE evaluation according to the latest IHN standard and AGHV pre-settings is available within a few minutes.

conclusionsAn on-line electronic platform for comprehensive assessment and centre-specific automated evaluation of AEs in haemaphereses has been developed and proved to be stable and safe over a period of 4 years.

Indexed as

Adverse eventsAdverse reactionsDonor safetyHaemapheresisHaemovigilancePlasmapheresisPlateletpheresisStem cell collection

Identifiers

PMID28626370
PMCPMC5473082
OpenAlexW2557635843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.